Lornoxicam

Lornoxicam
Clinical data
Trade names	Xefo, Xefocam others
AHFS/Drugs.com	International Drug Names
Pregnancy; category	Not recommended; contraindicated in months 7–9;
Routes of; administration	By mouth, parenteral
ATC code	M01AC05 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	90–100%
Protein binding	99%
Metabolism	CYP2C9
Elimination half-life	3–4 hours
Excretion	2/3 liver, 1/3 kidney
Identifiers
	IUPAC name (3E)-6-chloro-3-[hydroxy(pyridin-2-ylamino)methylene]-2-methyl-2,3-dihydro-4H-thieno[2,3-e][1,2]thiazin-4-one 1,1-dioxide;
CAS Number	70374-39-9 ;
PubChem CID	5282204;
DrugBank	DB06725 ;
ChemSpider	10442760 ;
UNII	ER09126G7A;
KEGG	D01866 ;
ChEBI	CHEBI:31783 ;
CompTox Dashboard (EPA)	DTXSID6046133 ;
ECHA InfoCard	100.158.646
Chemical and physical data
Formula	C13H10ClN3O4S2
Molar mass	371.81 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C(=C(C2=C(S1(=O)=O)C=C(S2)Cl)O)C(=O)NC3=CC=CC=N3;
	InChI InChI=1S/C13H10ClN3O4S2/c1-17-10(13(19)16-9-4-2-3-5-15-9)11(18)12-7(23(17,20)21)6-8(14)22-12/h2-6,18H,1H3,(H,15,16,19) ; Key:WLHQHAUOOXYABV-UHFFFAOYSA-N ;
	(what is this?) (verify)

Lornoxicam, also known as chlortenoxicam, is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic (pain relieving), anti-inflammatory and antipyretic (fever reducing) properties. It is available in oral and parenteral formulations.

It was patented in 1977 and approved for medical use in 1997.^[1] Brand names include Xefo and Xefocam among others.

^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 519. ISBN 9783527607495.